LAVA Therapeutics N.V.
NASDAQ:LVTX
1.26 (USD) • At close April 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 11.982 | 6.769 | 19.391 | 5.35 | 3.747 | 0 |
| Cost of Revenue
| 0 | 3.482 | 0 | 0 | 15.701 | 8.347 |
| Gross Profit
| 11.982 | 3.287 | 19.391 | 5.35 | -11.954 | -8.347 |
| Gross Profit Ratio
| 1 | 0.486 | 1 | 1 | -3.19 | 0 |
| Reseach & Development Expenses
| 28.45 | 33.814 | 40.105 | 36.945 | 15.701 | 8.347 |
| General & Administrative Expenses
| 13.225 | 12.726 | 14.124 | 12.018 | 2.719 | 1.236 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.225 | 12.726 | 14.124 | 12.018 | 2.719 | 1.236 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 41.675 | 46.54 | 51.306 | 46.923 | 3.588 | 1.254 |
| Operating Income
| -29.693 | -43.253 | -34.838 | -43.613 | -14.673 | -9.583 |
| Operating Income Ratio
| -2.478 | -6.39 | -1.797 | -8.152 | -3.916 | 0 |
| Total Other Income Expenses Net
| 3.949 | 1.558 | 3.18 | 1.415 | -1.211 | -0.104 |
| Income Before Tax
| -25.744 | -41.695 | -31.658 | -42.198 | -15.884 | -9.687 |
| Income Before Tax Ratio
| -2.149 | -6.16 | -1.633 | -7.887 | -4.239 | 0 |
| Income Tax Expense
| -0.63 | 0.279 | 0.249 | 0.157 | 0.043 | 0 |
| Net Income
| -25.114 | -41.974 | -31.907 | -42.355 | -15.927 | -9.687 |
| Net Income Ratio
| -2.096 | -6.201 | -1.645 | -7.917 | -4.251 | 0 |
| EPS
| -0.94 | -1.57 | -1.23 | -2.14 | -39.9 | -21.65 |
| EPS Diluted
| -0.94 | -1.57 | -1.23 | -2.14 | -39.9 | -21.65 |
| EBITDA
| -23.502 | -40.417 | -30.877 | -41.015 | -14.652 | -9.484 |
| EBITDA Ratio
| -1.961 | -5.971 | -1.592 | -7.666 | -3.91 | 0 |